MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ
49.43
-1.77
-3.46%
After Hours: 48.46 -0.97 -1.96% 17:39 05/15 EDT
OPEN
50.88
PREV CLOSE
51.20
HIGH
50.88
LOW
49.15
VOLUME
616.05K
TURNOVER
--
52 WEEK HIGH
59.68
52 WEEK LOW
30.83
MARKET CAP
2.87B
P/E (TTM)
-96.5618
1D
5D
1M
3M
1Y
5Y
1D
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
NASDAQ · 4d ago
Weekly Report: what happened at SUPN last week (0504-0508)?
Weekly Report · 5d ago
Supernus CEO joins Bank of America Health Care Conference fireside chat
PUBT · 05/06 21:49
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Barchart · 05/06 16:00
Stifel Nicolaus Reaffirms Their Hold Rating on Supernus Pharmaceuticals (SUPN)
TipRanks · 05/06 15:36
Supernus Reports Q1 Combined Sales Of $150 Mln; Updates CNS Therapies Pipeline
NASDAQ · 05/06 14:18
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
TipRanks · 05/06 11:59
SUPN: Buy Rating Reiterated as Strong Growth Supports Unchanged $65 Price Target
TipRanks · 05/06 04:05
More
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Its products include Qelbree, GOCOVRI, APOKYN, Trokendi XR, Oxtellar XR, ZURZUVAE, ONAPGO, XADAGO, and MYOBLOC. Qelbree is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients six years and older. GOCOVRI extended-release capsules are medicine indicated for the treatment of dyskinesia in patients with PD receiving levodopa-based therapy. It is also involved in developing product candidates in neurology and psychiatry, including SPN-817 (huperzine A), SPN-820 (NV-5138), and SPN-443.

Webull offers Supernus Pharmaceuticals Inc stock information, including NASDAQ: SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.